Tumor angiogenesis—the formation of new tumor-associated vasculature—has been recognized as an essential event in tumor progression. Vascular endothelial growth factor (VEGF), one of the most important factors involved in tumor angiogenesis, is overexpressed in several gastrointestinal cancers. In this Review, the authors consider antiangiogenic therapy for the treatment of colorectal, gastric, hepatocellular and pancreatic cancer. Emphasis is placed on the mechanism of action and application of the humanized anti-VEGF monoclonal antibody bevacizumab, but other potential antiangiogenic targets and therapies are also discussed.
- Anke Reinacher-Schick
- Michael Pohl
- Wolff Schmiegel